Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06627894

Attenuating DEPression With Internet CBT to Slow Cognitive Decline in Older ICU Survivors(ADEPT-ICU)

Depression affects one-third of intensive care unit (ICU) survivors and represents a potentially modifiable target to slow cognitive decline and reduce the risk of Alzheimer's disease and related dementias (ADRD). Our multi-PI team proposes a two-arm RCT called ADEPT-ICU (Attenuating DEPression with Internet CBT to Slow Cognitive Decline in Older ICU Survivors), which will test the efficacy of an internet CBT intervention called Good Days Ahead (GDA) to reduce the burden of subjective cognitive decline (SCD) in older ICU survivors with moderate to severe depressive symptoms after ICU hospitalization.

Recruiting

Interested in participating?

Request Info

Key information

Age range

50 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Eskenazi Hospital, Indianapolis, Indiana, United States

Loading trial locations.

About this study

Alzheimer's disease and related dementias (ADRD) affect 47 million people worldwide with an annual global cost of $818 billion. The risk of developing ADRD is disproportionately borne by older adults with multiple chronic conditions from underrepresented racial and ethnic groups (URGs). One such high risk group is older survivors of critical illness who were admitted to the intensive care units (ICUs). Nearly half of ICU survivors experience subjective cognitive decline(SCD), i.e., perceived decline in memory and thinking even with normal objective cognitive data. With over 5 million adult ICU admissions in the US each year, an intervention reducing SCD in older ICU survivors could significantly prevent or lower the incidence of ADRD. Thus, there is an urgent need for an inclusive randomized controlled trial (RCT) to rigorously test whether a novel, accessible, and scalable intervention can reduce SCD in a diverse cohort of older ICU survivors. One potential target for such interventions is post-ICU depression, which affects about one-third of ICU survivors. To date, there are no large scale RCTs which have rigorously tested whether depression focused psychotherapies, such as cognitive behavioral therapy (CBT), reduce SCD in a diverse cohort of older ICU survivors with depression.

We propose a two-arm, randomized, parallel-group, assessor-blinded clinical trial to evaluate the efficacy of internet CBT for depression compared to an active control in reducing SCD and slowing cognitive decline in older ICU survivors with post-ICU depression. The total duration of the intervention will be 6 months from randomization.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 50 years of age and older
  • Admitted to the intensive care for greater > 48 hours
  • Able to understand and provide informed consent
  • Elevated depressive symptoms, defined as Screening PHQ-9 or PHQ-8 ≥ 10 or Screening PHQ-9 or PHQ-8 = 5-9 with the presence a core symptom of anhedonia (PHQ-9 or PHQ-8 Item 1) or depressed mood (PHQ-9 or PHQ-8 Item 2)
  • Willing to participate in cognitive testing
  • Access to a telephone
  • Discharge to home or an independent or assisted living facility
  • Response is a 1,2, or 3 on PHQ-9 or PHQ-8 item 7, answered yes to "Have you experienced a change in your memory or other aspect of thinking in the past 1 to 3 years?", or score in the 25% percentile or lower on the Montreal Cognitive Assessment (MOCA) based on normative data which account for age, gender, race, ethnicity and education.

Exclusion criteria

  • Diagnosis of dementia or neurodegenerative disease (e.g. Alzheimer's disease, vascular dementia as per EHR and IQCODE, or Parkinson's disease) or on anti-dementia medications prior to ICU stay
  • Diagnosis of severe mental illness (bipolar disorder, schizophrenia, schizoaffective) as per EHR and screening questions
  • Persistent psychotic symptoms after ICU stay which would interfere with successful completion of intervention
  • Recent or recurrent alcohol or substance use disorder as per HER and Drug Abuse Screening Test
  • Life expectancy less than 1 year (e.g. terminal cancer diagnosis, discharged on hospice)
  • Ischemic or hemorrhagic stroke, traumatic brain injury, or undergoing neurosurgery prior, during or after ICU stay
  • Uncorrected visual or auditory impairment including legal blindness or deaf
  • Status post tracheostomy and not able to communicate
  • Incarcerated or on parole after ICU stay

Treatment and study plan

Therapist-Assisted Internet Cognitive-Behavioral Therapy for Depression

Behavioral

Good Days Ahead (MindStreet, Inc.)

Active Control

Behavioral

Depression education, symptom monitoring, and standard depression care

Primary outcomes

  1. Subjective Cognitive Decline

    Time frame: Measured at 6-month and 12-month follow-up.

    The primary outcome will be subjective cognitive decline (SCD), measured using the Cognitive Change Index self-report version (CCI-SR).

Secondary outcomes

  1. Cognition status

    Time frame: Measured at 6-month and 12-month follow-up.

    Repeatable Battery for Assessment of Neuropsychological Status (RBANS)

  2. Quality of Life physical and mental component status

    Time frame: Measured at 6-month and 12-month follow-up.

    Medical Outcome Study Short Form (SF-36)

Study contacts

Contact information is provided by the study sponsor or research team.

Babar Khan, MD, MS

CONTACT

[email protected]

317-274-9132

Lori Rawlings, RN, BSN

CONTACT

[email protected]

317-274-9052

Sponsors and collaborators

Lead sponsor

Indiana University

Other

Collaborators

  • National Institute on Aging (NIA)

Registry information

Acronym: ADEPT-ICU

Important dates

Study start
2025
Primary completion
2029
Study completion
2029
First posted
Oct 4, 2024
Registry last updated
Dec 17, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.